Go Pro
NASDAQ:BTTC

Black Titan Q2 2026 Earnings Report

Black Titan logo
$0.36 0.00 (-0.96%)
As of 11:19 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Black Titan EPS Results

Actual EPS
-$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Black Titan Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Black Titan Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Black Titan Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
See More Black Titan Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Titan? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Titan and other key companies, straight to your email.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

View Black Titan Profile